A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes

A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes

The current study aimed to evaluate the efficacy of sitagliptin vs. placebo in treating non-alcoholic fatty liver disease (NAFLD). In a triple-blind randomized clinical trial, we assigned 120 eligible subjects with NAFLD to receive daily dosing of 50 mg sitagliptin (n = 60) or the placebo (n = 60) f...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Azam Doustmohammadian, Ahmad Nezhadisalami, Fahimeh Safarnezhad Tameshke, Nima Motamed, Mansooreh Maadi, Mohammad Farahmand, Masoudreza Sohrabi, Cain C. T. Clark, Hossein Ajdarkosh, Amir Hossein Faraji, Mehdi Nikkhah, Elham Sobhrakhshankhah, Ramin Ebrahimi, Farhad Zamani
التنسيق: مقال
اللغة:English
منشور في: Frontiers Media S.A. 2022-07-01
سلاسل:Frontiers in Medicine
الموضوعات:
sitagliptin
NAFLD
clinical trial design
fibrosis scores
liver enzymes
الوصول للمادة أونلاين:https://www.frontiersin.org/articles/10.3389/fmed.2022.937554/full

الانترنت

https://www.frontiersin.org/articles/10.3389/fmed.2022.937554/full

مواد مشابهة